Abstract 859P
Background
Endometrial cancer prognosis is generally favorable, thus efforts to improve patient care focus on reducing morbidity with maintained good outcome and increasing health-related quality of life (HRQL). We explored HRQL parameters in a Norwegian multicenter endometrial cancer cohort and the impact of important treatment modalities.
Methods
Endometrial cancer patients surgically treated at Norwegian centers participating in the Molecular Markers in the treatment of Endometrial Cancer 2 trial (MoMaTEC2, Clingov ID NCT02543710) were asked to complete EORTC QLQ-C30 and EN24 questionnaires online preoperatively and annually post-treatment. Clinical data was obtained from medical records. Questionnaires completed from October 2015 until November 2019 were assessed with the EORTC scoring manual, and baseline and longitudinal differences in HRQL parameters were explored. MoMaTEC2 is IRB approved (REK2015/548) and informed consent is mandatory.
Results
Baseline data was available for 345 patients, with follow-up data for 235 patients at year 1 and 138 at year 2. The mean global health status (GHS) was significantly lower at baseline than at year 1 (p<0.001). Several functional scales significantly increased at year 1, most notably emotional functioning (+10.9, p<0.001). At year 2, physical functioning decreased significantly compared to baseline (-4.4, p=0.019). In subgroup analysis, 35% of patients who underwent any lymph node removal (LNR) reported increasing lymphedema scores, producing a significant mean increase (+7.6, p<0.001). Tingling/numbness likewise increased in 39% (mean +18.8, p<0.001). Patients treated with adjuvant chemotherapy reported similar increases in symptoms, lower physical functioning at year 1 (-6.9, p=0.005), and showed no improvement in GHS, as opposed to patients that did not receive chemotherapy.
Conclusions
Self-assessed HRQL increases from diagnosis time-point to follow up, possibly due to disease/emotional stress at diagnosis. Chemotherapy is associated with a long-term reduction in physical functioning and lack of improvement of GHS. LNR seems to have little effect on overall HRQL, but some treated patients experience symptoms as assessed by the EORTC scales.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Haukeland University Hospital.
Funding
Norwegian Cancer Association, The Research Council of Norway, The Western Norway Regional Health Authority.
Disclosure
All authors have declared no conflicts of interest.